Technology
Health
Biotechnology

Sophiris Bio

$0.7893
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.012 (-1.55%) Today
+$0.0266 (3.49%) After Hours

Why Robinhood?

You can buy or sell Sophiris Bio and other stocks, options, ETFs, and crypto commission-free!

About

Sophiris Bio, Inc. Common Stock, also called Sophiris Bio, is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. Read More The firm develops PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.

Employees
6
Headquarters
La Jolla, California
Founded
2003
Market Cap
23.41M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
309.64K
High Today
$0.79
Low Today
$0.75
Open Price
$0.78
Volume
22.96K
52 Week High
$4.05
52 Week Low
$0.7213

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2013 IPO
US

Earnings

-$0.20
-$0.16
-$0.12
-$0.08
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.10 per share
Actual
-$0.08 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.